PID6: HEALTH-RELATED QUALITY OF LIFE CHANGES IN PATIENTS WITH ONYCHOMYCOSIS  by Lubeck, DP et al.
184 Abstracts
differences became apparent regarding issues such as pri-
vacy, which was of greater concern to Italian patients than
US patients, and bureaucratic issues surrounding drug
availability, which were difficult for some US patients but
not for Italian patients. Finally, in response to patient sug-
gestions, the questionnaire includes positive wording
about “taking” rather than “missing” medication. 
CONCLUSION: In this small group of patients, the
PMAQ7 was judged to be relevant for patients, offering a
promising initial indication of the validity of the instru-
ment to monitor and manage adherence to antiretroviral
therapy.
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OBJECTIVES: The objective of the study was to examine
changes in health-related quality of life (HRQoL) in an
observational database of patients with onychomycosis
receiving various treatments by either dermatologists or
podiatrists. 
METHODS: Dermatologists or podiatrists at eight US
sites reported on clinical outcomes at baseline and follow-
up (4 and 9 months). Patients completed a validated
HRQoL questionnaire at the same time points that mea-
sured the impact of onychomycosis on generic (general
health perception, pain, mental health, social functioning,
health distress, physical functioning, and health transition)
and disease-specific items (toe symptom frequency, toe
symptom bother, problems with appearance, problems
with activities, stigma, and satisfaction with treatment). 
RESULTS: For this study 113 patients completed the
questionnaire at baseline and follow-up. Forty-eight per-
cent of patients were treated by dermatologists, 52% by
podiatrists. Patients were predominately male (58%). At
month 9, patients treated with oral antifungal therapy had
significant improvements in physical functioning, toenail
symptoms, toenail bother, problems with appearance and
activities, stigma, pain and satisfaction with treatment
(p  0.01) when compared with patients treated with non-
oral therapy. 
CONCLUSION: The data indicate that patients with on-
ychomycosis who seek treatment with oral therapy re-
port significant improvement in HRQoL and satisfaction
compared with patients treated with non-oral therapy.
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OBJECTIVE: The purpose of this study was to evaluate
cost per mycological treatment of oral antifungal drugs
and to determine the most cost-effective primary treatment
for onychomycosis using the Idaho Medicaid claims data. 
METHOD: Oral griseofulvin, itraconazole, ketoconazole,
fluconazole, and terbinafine were the antifungal drugs used
to determine the cost per mycological treatment and relative
cost-effectiveness ratios. The Idaho Medicaid database was
screened using ICD-9 code, from October 1992 to Novem-
ber 1998 to identify patients receiving treatment for ony-
chomycosis. Five hundred and forty-nine patients using one
antifungal drug were identified and were followed for a pe-
riod of 1 year following a diagnosis of fungal infection of
the nail and an associated prescription of an antifungal
agent. Costs for drugs, physician visits, and drug manage-
ment was used in the treatment model. CPT codes were
used to identify laboratory cost involved in drug manage-
ment. The Mycological cure rates obtained from clinical tri-
als reported in literature were used as a measure of treat-
ment efficacy. Relative cost-effectiveness was calculated
assigning a value of 1.0 to terbinafine. 
RESULTS: The mean total treatment cost for each pa-
tient for griseofulvin was $460.72, for itraconazole was
$872.91, for ketoconazole was $464.78, for fluconazole
was $216.80, and that of terbinafine was $186.57. Ter-
binafine also had the lowest cost ($230.33) per mycolog-
ical treatment after adjusting for cure rates, for one treat-
ment regimen. Relative cost-effectiveness for griseofulvin
was 2.94, for itraconazole 4.07, for ketoconazole 3.36,
and fluconazole was 1.58. 
CONCLUSIONS: Terbinafine was found to be a more
cost-effective primary drug compared to griseofulvin,
itraconazole and ketoconazole in the treatment of ony-
chomycosis. Fluconazole was found to be the second
most cost-effective next to terbinafine.
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OBJECTIVE: A retrospective analysis to compare cost,
days of therapy, and demographic data for patients on
antifungal therapies for nail involvement in a Medicaid
population. 
METHOD: Diagnosis codes combined with antifungal
medications were used to identify patients on different
therapies for onychomycosis. Griseofulvin, itraconazole,
ketoconazole, fluconazole, and terbinafine were the oral
antifungal drugs compared. Drug costs and physician costs
were analyzed. The total number of different medications,
other than those for onychomycosis, was used as a mea-
sure of health. Demographic variables of age and gender
were evaluated. 
